177 related articles for article (PubMed ID: 37836440)
1. Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT.
Melekoglu E; Bayram E; Secmeler S; Mete B; Sahin B
Nutrients; 2023 Sep; 15(19):. PubMed ID: 37836440
[TBL] [Abstract][Full Text] [Related]
2. [Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy].
Cui Y; Li J; Cao YH; Liu MY; Shi ZX; Gao TH
Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):195-200. PubMed ID: 28316218
[No Abstract] [Full Text] [Related]
3. The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.
Tian R; Zhang F; Sun P; Wu J; Yan H; Wu AR; Zhang M; Jiang YL; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
Oncotarget; 2016 Oct; 7(41):67485-67494. PubMed ID: 27528228
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer.
Hirashima K; Watanabe M; Shigaki H; Imamura Y; Ida S; Iwatsuki M; Ishimoto T; Iwagami S; Baba Y; Baba H
J Gastroenterol; 2014 Jun; 49(6):1040-6. PubMed ID: 23821018
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
6. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
[No Abstract] [Full Text] [Related]
7. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
[TBL] [Abstract][Full Text] [Related]
8. Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer.
Otowa Y; Nakamura T; Takiguchi G; Tomono A; Yamamoto M; Kanaji S; Imanishi T; Suzuki S; Tanaka K; Itoh T; Kakeji Y
Dis Esophagus; 2016; 29(2):146-51. PubMed ID: 25515972
[TBL] [Abstract][Full Text] [Related]
9. Modified Glasgow prognostic score can predict survival of muscle invasive bladder cancer patients after radiotherapy.
Kikuchi K; Nakamura R; Segawa T; Oikawa H; Ariga H
J Radiat Res; 2020 Jul; 61(4):616-621. PubMed ID: 32567660
[TBL] [Abstract][Full Text] [Related]
10. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Treatment Response and Survival with Chemotherapy for Metastatic Penile Cancer by the Modified Glasgow Prognostic Score.
Draeger DL; Groh S; Buchholz T; Woehl M; Nolting J; Hakenberg OW
Urol Int; 2023; 107(5):489-495. PubMed ID: 34610603
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
[TBL] [Abstract][Full Text] [Related]
14. Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: A propensity score-matched analysis.
Cui C; Wu X; Deng L; Wang W; Cui W; Wang Y
Thorac Cancer; 2022 Jul; 13(14):2041-2049. PubMed ID: 35624549
[TBL] [Abstract][Full Text] [Related]
15. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer.
Takeno S; Hashimoto T; Shibata R; Maki K; Shiwaku H; Yamana I; Yamashita R; Yamashita Y
Oncology; 2014; 87(4):205-14. PubMed ID: 25034097
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
[TBL] [Abstract][Full Text] [Related]
17. Inflammation-based prognostic scores in geriatric patients with rectal cancer.
Manoglu B; Sokmen S; Bisgin T; Semiz HS; Görken IB; Ellidokuz H
Tech Coloproctol; 2023 May; 27(5):397-405. PubMed ID: 36197565
[TBL] [Abstract][Full Text] [Related]
18. Prognostic efficacy of preoperative mGPS, SIS and LCS in patients with gastric cancer.
Chen YR; Chen YL; Ouyang SS; Xu HW; Li P; He LJ; Zhu SL
Clin Chim Acta; 2020 Dec; 511():81-89. PubMed ID: 33002476
[TBL] [Abstract][Full Text] [Related]
19. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.
Hacker UT; Hasenclever D; Baber R; Linder N; Busse H; Obermannova R; Zdrazilova-Dubska L; Valik D; Lordick F
Ann Oncol; 2022 Jul; 33(7):685-692. PubMed ID: 35395383
[TBL] [Abstract][Full Text] [Related]
20. A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy.
Hsieh MC; Wang SH; Chuah SK; Lin YH; Lan J; Rau KM
Medicine (Baltimore); 2016 Apr; 95(17):e3504. PubMed ID: 27124056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
